Benzinga | Jul 20, 2020 08:04AM EDT

GEMoaB And Intellia Therapeutics Enter Into Research Collaboration And Licensing Agreement On Next-Generation Cellular Immunotherapy Based On Proprietary RevCAR And CRISPR/Cas9 Genome Editing Platforms

DRESDEN, Germany, July 20, 2020 /PRNewswire/ -- GEMoaB, a biopharmaceutical company focused on the development of next-generation immunotherapies for hard-to-treat cancers, announced today that it has entered into a research collaboration and license agreement with Intellia (NASDAQ:NTLA), a global leader in the field of genome editing treatments.